Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.
复制标题
DOI：
10.1007/s00401-011-0861-8
复制
发表时间：
2011-10
影响因子：
12.7
通讯作者：
Alzheimer’s Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Toledo JB;Vanderstichele H;Figurski M;Aisen PS;Petersen RC;Weiner MW;Jack CR Jr;Jagust W;Decarli C;Toga AW;Toledo E;Xie SX;Lee VM;Trojanowski JQ;Shaw LM;Alzheimer’s Disease Neuroimaging Initiative
先前关于β血浆作为阿尔茨海默病(AD)生物标记物的研究得出了相互矛盾的结果。我们纳入了715例基线Aβ1-40和Aβ1-42的受试者，其中认知正常对照组205例，轻度认知损害组348例，AD组162例。我们评估了改变其浓度的因素，并将这些值与脑脊液中的PIBPET、MRI、Tau和Aβ1-42测定相关联。评估Aβ与诊断(基线和前瞻性)之间的相关性。许多健康状况与血浆A-β浓度的变化有关。年龄的影响因AD分期不同而不同。血浆A-β1-42与A-β病理的其他生物标志物呈轻度相关，并与磁共振成像中的脑梗塞有关。对Aβ1-40和Aβ1-42血浆水平的纵向测量显示，作为临床进展的预后因素有适度的价值。我们对A-β病理(脑脊液、脑脊液和血浆A-β)和其他生物标记物的互补指标的纵向研究具有重要意义，因为它表明，血浆A-β测定对疾病分类的价值有限，在3年的随访中作为预后因素的价值不大。然而，随着时间的延长，在受试者中，血浆Aβ测量可以作为一种简单和微创的筛查方法来识别那些AD风险增加的人。我们的研究强调需要更好地了解血浆Aβ的生物学和动力学，以及需要进行更长期的研究来确定测定血浆Aβ的临床实用价值。
Previous studies of Aβ plasma as a biomarker for Alzheimer’s disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ1–40 and Aβ1–42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ1–42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ1–42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ1–40 and Aβ1–42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.
登录
查看更多内容
影响因子：
4
作者：
Laske, Christoph;Sopova, Kateryna;Stellos, Konstantinos
通讯作者：
Stellos, Konstantinos
影响因子：
11
作者：
de Souza, Leonardo Cruz;Lamari, Foudil;Sarazin, Marie
通讯作者：
Sarazin, Marie
影响因子：
9.9
作者：
Gurol, ME;Irizarry, MC;Greenberg, SM
通讯作者：
Greenberg, SM
DOI：
10.1016/j.jalz.2010.03.003
发表时间：
2010-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Jagust WJ;Bandy D;Chen K;Foster NL;Landau SM;Mathis CA;Price JC;Reiman EM;Skovronsky D;Koeppe RA;Alzheimer's Disease Neuroimaging Initiative
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
影响因子：
11.1
作者：
Fagan, Anne M.;Mintun, Mark A.;Shah, Aarti R.;Aldea, Patricia;Roe, Catherine M.;Mach, Robert H.;Marcus, Daniel;Morris, John C.;Holtzman, David M.
通讯作者：
Holtzman, David M.